Skip to main content
Equibles
IDXX logo

IDXX · Idexx Laboratories Inc /De

Track IDXX — free Ask ALVIS about IDXX
$586.67 -3.33 (-0.56%) At close · Aug 7
Market Cap
$46.22B
Shares
78.78M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$586.67 Open$587.74 Day$583.44–600.84 52W$518.55–769.98 Avg vol 30d697K Short int2.1M · 2.7% float · 3.0d Short vol46% Last earningsAug 4, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 4

Up next

Next earnings call
Nov 3, 2026 Est · unconfirmed · in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 4, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Neutral
      SellHoldBuy
      Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
      Market backdrop VIX 14.9 · calm Equity put/call 0.54
      Technical
      price trend
      Neutral
      50 / 200-day cross No cross
      Price vs 200-day avg −5%
      below
      Price vs 50-day avg +5%
      above
      RSI (14) 60
      neutral
      MACD trend Positive
      52-week position 27%
      mid-range
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Weak
      1-month return +4%
      trailing
      6-month return −7%
      trailing
      YTD return −13%
      this year
      Relative strength −20%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $560 › 200d $619 — 200d above 50d
      Institutional flow Accumulating
      782 of 1,314 funds reported for Jun 30 · net +361.1K sh shares · +57 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      2.67% of float · ▲ +8.3% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      1,314 holders — mid 3-yr range
      Squeeze score 53
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +10%
      Y/Y
      Gross margin 62%
      expanding
      EPS growth +23%
      Y/Y
      Free cash flow $1.1B
      Valuation P/E 41.2
      rich
      Balance sheet $269.8M
      net debt
      Quant / Vol
      risk profile
      Moderate
      Volatility 32%
      annualized · 1-yr
      Max drawdown −31%
      past year
      ATR 3.4%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 4
      Latest guidance · from the 8-K filed Aug 4, 2026
      Revenue · 2026 Growth and Financial Performance Outlook Raised $4.7B – $4.75B
      prior FY $4.3B midpoint +9.7% Y/Y
      Reported revenue growth · 2026 Growth and Financial Performance Outlook Raised 9.1% – 10.3%
      CAG Diagnostics Recurring Revenue Organic growth · 2026 Growth and Financial Performance Outlook Raised 9.5% – 10.7%
      Organic revenue growth · 2026 Growth and Financial Performance Outlook Raised 8.5% – 9.7%
      CAG Diagnostics Recurring Revenue Reported growth · 2026 Growth and Financial Performance Outlook Initiated 10.1% – 11.3%
      Operating Margin · 2026 Growth and Financial Performance Outlook Initiated 32.3% – 32.5%
      EPS Comparable growth · 2026 Growth and Financial Performance Outlook Initiated 13% – 15%
      EPS Reported growth · 2026 Growth and Financial Performance Outlook Initiated 12% – 14%
      Net interest expense · 2026 Growth and Financial Performance Outlook $35M
      EPS · 2026 Growth and Financial Performance Outlook Raised $14.69 – $14.94
      prior FY $13.08 midpoint +13.3% Y/Y
      Effective tax rate · 2026 Growth and Financial Performance Outlook 21.1%
      Share-based compensation tax benefit · 2026 Growth and Financial Performance Outlook $19M
      Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
      Full year overall revenue · full year 2025 $4.27B – $4.3B
      Full year overall organic revenue growth · full year 2025 8.8% – 9.5%
      Full year free cash flow conversion · full year 2025 95% – 100%
      Full year EPS · full year 2025 $12.81 – $13.01
      Organic CAG Diagnostics recurring revenue growth · full year 2025 7.5% – 8.2%
      Guided vs delivered · last 4 settled
      Full year overall revenue full year 2025
      guided $4.27B – $4.3B
      $4.3B Beat +0.4%
      Full year EPS full year 2025
      guided $12.81 – $13.01
      $13.08 Beat +1.3%
      Reported revenues full year 2024
      guided $3.9B – $3.97B
      $3.9B In line
      EPS full year 2024
      guided $10.82 – $11.20
      $10.67 Miss −3.1%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Neutral
      1 · 4 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −5% Bearish
      Price vs 50-day avg
      +5% Bullish
      RSI (14)
      60 Neutral
      MACD trend
      Positive Bullish
      52-week position
      27% Neutral
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $560 › 200d $619 — 200d above 50d
      Institutional flow Accumulating
      782 of 1,314 funds reported for Jun 30 · net +361.1K sh shares · +57 new
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      2.67% of float · ▲ +8.3% MoM · 3.0 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      1,314 holders — mid 3-yr range
      Price context
      position in its 52-week range
      52-wk low $519 Now $587 · 27% 52-wk high $770
      vs 200-day avg -5% vs 50-day avg +5%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from its earnings releases, calls, and filings
      Metric Latest Period YoY
      CAG Diagnostics capital instrument revenue growth 76% Q4 FY2025 —
      CAG Diagnostics capital instrument revenue organic growth 69% Q4 FY2025 —
      CAG Diagnostics recurring revenue growth 9% Full Year FY2025 —
      CAG Diagnostics recurring revenue organic growth 8% Full Year FY2025 —
      comparable gross margin gain non-GAAP 60 Q4 FY2025 —
      comparable gross profit growth non-GAAP 11% Full Year FY2025 —
      comparable operating expense growth non-GAAP 9% Full Year FY2025 —
      comparable operating margin expansion non-GAAP 90 Full Year FY2025 —
      new and competitive Catalyst placements 1,400 Q4 FY2025 —

      Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      IDXX
      Idexx Laboratories Inc /De
      this stock
      		$46.22B -13.3% +10.4% 41.2 2.7%
      TMO
      Thermo Fisher Scientific Inc.
      		 $219.63B +2.7% +0.4% 32.0 1.4%
      DHR
      Danaher Corp /De/
      		 $143.94B -10.2% +8.5% 36.3 1.4%
      NTRA
      Natera, Inc.
      		 $46.43B +40.6% -2.8% — 3.4%
      A
      Agilent Technologies, Inc.
      		 $41.23B +7.9% +6.4% 29.3 2.7%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      1,302
      % held
      86.6%
      Reported
      782 of 1,314
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      957
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      2.1M
      Days to cover
      3.0d
      Change
      +160.4K sh
      View
      Short Volume
      Short vol %
      46%
      As of
      Aug 7, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      32
      Value
      $17.6K
      As of
      Jun 29, 2026
      View
      Off-Exchange
      Off-exchange %
      48.7%
      Week of
      Jul 6, 2026
      Off-exch Lit
      View
      Smart Money
      Congressional Trades Sell
      Member
      April McClain Delaney
      Amount
      $1.0K–$15.0K
      Traded
      Jan 13, 2026
      View
      Financials
      Financials
      Revenue (FY)
      $4.3B
      Net income (FY)
      $1.1B
      EPS diluted
      $13.08
      View
      Buybacks
      Authorized
      shares 78.0M
      Remaining
      shares 3.7M
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 4, 2026
      This year
      11
      View
      Proposed Sales
      Value
      $1.1M
      Shares
      1.8K
      Filed
      Mar 3, 2026
      View
      Earnings & Events
      Earnings Calls Upcoming
      Next call
      Aug 13, 2026
      Last call
      Aug 4, 2026
      View
      Investor Relations
      Upcoming events
      1
      View

      Performance

      5D 20D 120D MTD YTD
      IDXX +4.9% +4.1% -6.8% +4.9% -13.3%
      SPY +3.5% +2.4% +13.4% +3.5% +13.4%
      vs SPY +1.4% +1.7% -20.2% +1.4% -26.7%

      Capital returns

      Buyback program · as of Dec 31, 2025
      Authorized
      shares 78.00M
      Spent (derived)
      shares 74.30M
      Remaining
      shares 3.70M
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 874716 CUSIP 45168D104 13F (30d) 684 filings 655 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)